It is to keep the pipeline moving as fast as possible to get drugs as far down the regulatory path as possible for the negotiations. Stopping or having a slower pace of these activities would not be in the best interest of the company valuation.
At times it takes money to make money and also why not take a little money and parrellel path drugs to the market….
Not sure why anyone would think this a a bad strategy, 4 months is still 4 months of testing and information gathering to keeping this train rolling!
This sort of work will cut anchor and let the ELTP ship sail into the valuation we all believe is possible, not aggressively pushing more on this front would keep us anchored in the harbor….